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Effects of host defense peptides B2RP, Brevinin-2GU, 
D-Lys-Temporin, Lys-XT-7 and D-Lys-Ascaphin-8 on 
peripheral blood mononuclear cells: Preliminary study
Abstract
Background and purpose: Host defense peptides have considerable 
therapeutic potential. One of the limitations for their therapeutic use is 
insufficient selectivity of some peptides, i.e. toxicity for eukaryotic cells. In 
this study, we have investigated effect of two naturally occurring and three 
analogs of frog skin-derived peptides on viability/proliferation of resting 
peripheral blood mononuclear cells and activated lymphocytes.
Materials and Methods: Effect of tested peptides was assessed using 
MTT colorimetric assay. Concanavalin A was used as lymphocyte mitogen.
Results: Brevinin-2GU induced cell death only in the highest tested 
concentration, whereas other peptides were not cytotoxic to resting periph-
eral blood mononuclear cells. Moreover, high concentrations of B2RP, D-
Lys-Ascaphin-8 and Lys-XT-7 induced cell proliferation and this effect was 
more prominent in lymphocytes (p<0.05). Tested peptides had opposite effect 
on activated lymphocytes inhibiting proliferative response to Concanavalin 
A (Brevinin-2GU, B2RP and D-Lys-Temporin p<0.05).
Conclusions: Tested peptides (with exception of Brevinin-2GU) didn’t 
show cytotoxicity toward peripheral blood mononuclear cells. Moreover, they 
have potential to modulate immune response by inducing proliferation of 
resting peripheral blood mononuclear cells and limiting proliferative response 
to the activation stimulus. Regarding their potent antimicrobial and low 
hemolytic activity this makes them good candidates for therapeutic use.
INTRODUCTION
Host defense peptides (HDPs) represent a heterogeneous group of positively charged, amphipathic molecules composed of 12 to 50 
amino acids, with diversity of properties. They are found in almost all 
living organisms, from bacteria to humans (1). HDPs have multiplicity 
of biological functions. They exert a broad-spectrum antimicrobial activ-
ity and therefore are often referred to as “natural antibiotics” (2). The 
structure and positive net charge of HDPs enable strong binding to 
negatively charged membranes of microorganisms, as well as cancer 
cells, that bear more negative net charge than healthy cell (3). Electro-
static binding to outer surface of cell is followed by disruption of mem-
brane structure, binding to vital intracellular molecules and interference 
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Although the most studied feature of HDPs is their 
antimicrobial activity, there are opinions that primary 
task of these peptides is immunomodulation. HDPs pro-
mote immune response to inflammation and at the same 
time restrain it, protecting organism from excessive reac-
tion that can be detrimental for the host (4). They have 
impact on both innate and adaptive immunity and coor-
dinate their action, influencing various processes, such as 
proliferation, chemotaxis, cytokine production and acti-
vation of adaptive immune response. Furthermore, HDPs 
participate in wound healing and neovascularization (5).
Currently, potential of HDPs as new therapeutic 
agents in infectious diseases, cancer and immune-related 
disorders is objective of increasing number of studies (6). 
However, although recognized as promising new drugs, 
there are some limitations for their use. These referre to 
their sensitivity to enzymatic degradation and inactiva-
tion in serum by albumins and low-density lipoproteins, 
inadequate tissue distribution and potential systemic tox-
icity owning to their inefficient specificity. To overcome 
these problems, modifications of peptide structure have 
been under study (7).
In the present study we have tested effects of five pep-
tides, selected on the basis of their high antimicrobial 
potency and low hemolytic activity. Naturally occurring 
peptides Brevinin-2GU (8) and brevinin-2-related pep-
tide-ERa (B2RP-ERa) (9) were isolated from the skin of 
the Asian frog Hylarana. Analogs [D4k]ascaphin-8, 
[G4K]XT-7 (10–12) and [T5k]temporin-DRa (13), show-
ing potent antimicrobial and low hemolytic activity, were 
derived from frog skin peptides that have shown broad-






GML.NH2), [D4k]ascaphin-8 (GFKkLLKGA AKA LV-
KTVLF.NH2), [G4K]XT-7 (GLLKPLLKIAAKVGSN 
LL.NH2) and [T5k]temporin-DRa (HFLGkLVNLAK-
KILNH2), supplied in crude form by GL Biochem Ltd. 
(Shanghai, China) and purified to near homogeneity by 
reverse-phase HPLC (>98%), were a gift from Dr. M. 
Conlon (United Arab Emirates University, Dubai, UAE).
Cell isolation and culture
Cells were isolated from peripheral blood of healthy 
volunteers. Our institutional Ethics Committee approved 
the study and prior to initiation written informed consent 
was obtained from all subjects according to the Declara-
tion of Helsinki. Peripheral blood mononuclear cells 
(PBMNC) were isolated by density gradient centrifuga-
tion (Histopaque 1077, Sigma, Germany), washed three 
times and finally suspended in the supplemented culture 
medium RPMI 1640 (Sigma, Germany). Lymphocyte 
population (PBL) was isolated from PBMNC by adher-
ence method (14). Cell number and viability were deter-
mined using Acridine orange/Ethidium bromide staining 
(all from Sigma, Germany).
Cell viability and proliferation assay
The effect of cationic peptides on peripheral blood 
mononuclear cells was determined by MTT assay that is 
widely used for assessing cell proliferation, cell viability, 
and/or cytotoxicity (15). Mononuclear cells or lympho-
cytes were grown in 96-well plates at a starting density of 
0.2x106 cells/well in presence of increasing doses (1, 5, 10 
and 20 μg/ml) of peptides or in medium alone (control). 
In some experiments Concanavalin A (ConA) was used 
(5μg/ml). Cells were cultured for 24h at 37°C in 5% C02. 
Cultured cells viability was determined by assaying the 
reduction of MTT to formazan.
Statistics
The data were expressed as the mean ± SD. The distri-
butions of data were evaluated for normality using the 
Kolmogorov-Smirnov test. One-way ANOVA was per-
formed to compare parametric data between more than 
two groups. When ANOVA indicated significant differ-
ences, the Bonferroni test was used to identify intergroup 
differences. All statistical analyses were carried out with 
commercial statistical software (SPSS version 13.0; SPSS 
Inc., Chicago, IL).
RESULTS
The effect of peptides on cell viability
As shown in Figure 1., naturally occurring peptide 
Brevinin-2GU was slightly cytotoxic for PBMNC and 
PBL, but only the highest concentration (20μg/ml) de-
creased PBMNC viability with statistical significance 
(p<0.05), whereas effect on PBL was similar, but with no 
statistical significance. The other naturally occurring pep-
tide, B2RP-ERa, didn’t show significant cytotoxicity to-
ward PBMNC. However, it demonstrated opposite effect 
on PBL, inducing cell proliferation reaching statistical 
significance with the highest concentrations of 10 and 
20μg/ml (p<0.05). Similarly, analogs [D4k]ascaphin-8, 
[G4K] XT-7 and [T5k] temporin-DRa did not show cy-
totoxic effect to PBMNC and PBL in either concentration 
tested, while, in contrast, promoted proliferation of both 
PBMNC and PBL. However, this effect was noticeable 
only with the highest concentration (20μg/ml) of [D4k]
ascaphin-8, reaching statistical significance for PBL 
(p<0.05), and [G4K] XT-7, achieving significance for 
both PBL (p<0.001) and PBMNC (p<0.05). Importantly, 
this mitogenic action of both [D4k]ascaphin-8 and 
[G4K] XT-7 was more prominent in PBL (p<0.05).
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Peripheral blood mononuclear cells (PBMNC) and 
purified lymphocytes (PBL) were incubated for 24h in 
media alone (control) and with increasing doses (1, 5, 10 
and 20 μg/ml) of peptides. Cytotoxic or proliferative ef-
fect of peptides is presented as percent of change in cell 
number related to control. The values represent the mean 
(±SD) of five different experiments. *p<0.05; **p<0.001
Peptides diminished mitogenic effect 
of ConA
To determine whether tested peptides have influence 
on proliferative response induced by Concanavalin A, 
PBLs were incubated in media alone (control), or treated 
with 5μg/ml ConA, either in absence or presence of dif-
ferent concentration of peptides. Our results showed that 
peptides decrease the mitogenic action of ConA (Figure 
2.), and this effect was dose-dependent in that way that 
increase in concentration of peptides resulted in enhanced 
inhibition of ConA induced PBL proliferation.
Peripheral blood lymphocytes (PBL) were incubated 
for 24h in media alone (control) and with Concanavalin 
A (Con A) (5μg/ml) either in presence or absence of pep-
tides (1, 5, 10 and 20 μg/ml). Proliferative response in-
duced by ConA and influence of tested peptides on the 
response are presented as percent of change in cell number 
related to control. The values represent the mean (±SD) 
of five different experiments. *p<0.05
The most potent immunomodulator of all was 
Brevinin-2GU, that at the highest concentrations (10 and 
20μg/ml) significantly inhibited ConA-induced prolif-
eration of PBL, and this effect was most pronounced at a 
concentration of 20μg/ml which almost completely nul-
lifies the effect of ConA (p<0.05). Other peptides showed 
a similar effect, but statistically significant inhibition of 
the mitogenic action of Con A, although somewhat less 
than the Brevinin-2GU, showed only the highest concen-
trations (10 and 20μg/ml) of naturally occurring peptide 
B2RP-ERa and analog [T5k]temporin-DRa (p<0.05).
Summarized results are presented in Figure 3.
The effects of host defense peptides on peripheral blood 
mononuclear cells.
Figure 1. The effect of peptides on PBMNC and PBL.
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DISCUSSION
In spite of great potential of HDPs as new therapeutics, 
development of HDP-based drugs is limited by several 
shortcomings, such as instability and insufficient specific-
ity. Therefore, a number of investigations are directed 
toward designing analogs of naturally occurring peptides 
that will outpass these disadvantages. In this study we 
have investigated effect of two naturally occurring pep-
tides and three analogs on healthy peripheral blood 
mononuclear cells.
Our results showed that, apart from Brevinin-2GU 
that was cytotoxic in the highest concentration, tested 
HDP analogs and naturally occurring peptide B2RP-ERa 
didn’t exhibit cytotoxicity against mononuclear cells iso-
lated from peripheral blood, but rather promoted their 
proliferation. Our results are consistent with reports cer-
tifying that HDPs can enhance proliferation of periph-
eral blood mononuclear cells (16), which is in accordance 
with findings about impact of HDPs on immune system 
response (17).
Figure 2. Peptides decreased mitogenic effect of ConA.
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Activated lymphocytes can be, however, more sensitive 
to HDPs. The foregoing results have shown that tested 
peptides had more pronounced effect on macrophage de-
pleted peripheral blood mononuclear cells (PBL). Macro-
phages are necessary for many lymphocyte functions, 
including activation and mitogenic response, but can also 
suppress lymphocyte activation. Furthermore, macro-
phages can uptake culture medium with peptides via en-
docytosis and thus reduce their concentration beneath the 
effective doses required for the effect observed on lym-
phocytes. Therefore, to exclude influence of macrophages 
and to test effect of peptides on activated lymphocytes, 
we incubated PBLs with T-cell mitogen ConA, alone or 
with different concentration of tested peptides.
All tested peptides decreased proliferative effect of 
ConA in that way that higher concentration of peptides 
resulted in higher inhibition. This effect was most prom-
inent with naturally occurring peptides Brevinin-2GU 
and B2RP-ERa and analog [T5k]temporin-DRa (p<0.05). 
This effect of tested peptides can be a result of their cyto-
toxicity against activated lymphocytes. Nevertheless, in 
our previous study we have shown that tested peptides 
inhibited release of proinflammatory cytokines TNFα 
and IFNγ and stimulated release of antiinflammatory 
cytokines IL-4, IL-10 and TGFβ in ConA-stimulated 
PBLs (18). It is well known that IL-4, IL-10 and TGFβ 
can promote cell-cycle arrest and apoptosis (19, 20). 
Therefore it is possible that tested peptides exert their an-
tiproliferative activity through stimulation of antiinflam-
matory cytokines release. In any case, these results point 
to their capability to influence immune response.
In conclusion, we have shown that tested peptides (ex-
cept Brevinin-2GU) are not cytotoxic for resting periph-
eral blood mononuclear cells and even induce cell prolif-
eration, and that both naturally occurring peptides and 
analog [T5k]temporin-DRa have potential to modulate 
immune response to the activation stimulus. Concerning 
their high antimicrobial potency and low hemolytic activ-
ity, these peptides can be considered as potential thera-
peutics.
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